http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Statistical applications from clinical trials and personalized medicine to finance and business analytics
selected papers from the 2015 ICSA/Graybill Applied Statistics Symposium, Colorado State University, Fort Collins
Graybill Conference 2015 : Fort Collins, Colo.)
Preface; Contents; Contributors; Part I Biomarker and Personalized Medicine; Optimal Biomarker-Guided Design for Targeted Therapy with Imperfectly Measured Biomarkers; 1 Introduction; 2 Methods; 2.1 Optimal Allocation Rules; 2.2 Likelihood Ratio Test Based on EM Algorithm; 3 Simulation Studies; 4 Conclusion; Appendix; Proof of Theorem 1; Proof of Theorem 2; References; Statistical Considerations for Evaluating Prognostic Biomarkers: Choosing Optimal Threshold; 1 Introduction; 2 A Brief Review of the ROC Curve; 3 Criteria Based on the ROC Curve; 4 Issues When Reporting the Optimal Threshold
5 Simulation Study6 Discussion; References; Accuracy of Meta-Analysis Using Different Levels of Diagnostic Accuracy Measures; 1 Introduction; 2 Methods; 2.1 Definitions of Diagnostic Accuracy Measures; 2.2 A Bivariate Normal Model for Data Generation for Simulation Studies; 2.3 Meta-Analysis for Level 1 Data; 2.4 Meta-Analysis for Level 2 Data; 2.5 Meta-Analysis for Level 3 Data; 2.6 Simulation Experiments; 3 Simulation Results; 4 Discussion; References; Part II Bayesian Methods and Applications; Bayesian Frailty Models for Multi-State Survival Data; 1 Introduction; 2 BMT Data; 3 Models
3.1 Model for Immediate Child States3.2 Models for the Gap Times with Path Specific Frailty; 3.3 Likelihood Function; 3.4 Path Probability; 3.5 Relapse Free Probability; 4 Bayesian Inference; 4.1 Prior and Posterior Distributions; 4.2 Bayesian Computations and Model Comparison; 5 Analysis of the BMT Data; 6 Discussion; References; Bayesian Integration of In Vitro Biomarker to Analysis of In Vivo Safety Assessment; 1 Introduction; 2 Methods; 2.1 In Vivo Telemetry Study; 2.2 Statistical Analysis Method; 2.3 The Bayesian Model; 2.4 Posterior Inference; 3 Analysis and Results; 4 Discussion
Part III Dose Ranging Studies in Clinical TrialsSample Size Allocation in a Dose-Ranging Trial Combined with PoC; 1 Background; 2 Number of Doses and Control Groups; 3 Was the Concept Proven?; 4 Comparison of Power; 4.1 Four-Arm Study; 4.2 Five-Arm Study; 5 Discussion; References; Personalized Effective Dose Selection in Dose Ranging Studies; 1 Introduction; 2 Methods; 2.1 Context, Notation and Model; 2.2 Estimation: The INIA Method; 3 Numerical Examples; 3.1 Examples and Evaluation Criteria; 3.2 Single Marker Examples; 3.3 A Two-Marker Example; 3.4 A Multi-Marker Example; 4 Discussion
Jianchang Lin, Bushi Wang, Xiaowen Hu, Kun Chen, Ray Liu, editors.